ADMA / NO

• Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM. ADMA increases arterial stiffness and decreases cerebral blood flow in human. Stroke 2006, 36: e-pub ahead of print. PDF
• Zoccali C and Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens. 2006;15(3):314-320. PDF
• Menne J, Park JK, Agrawal R, Lindschau C, Kielstein JT, Kirsch T, Marx A, Muller D, Bahlmann FH, Meier M, Bode-Boger SM, Haller H, Fliser D. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J. 2006 [Epub ahead of print]. PDF
• Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2005;DOI 10.1007/s00228-005-0010-1. PDF
• Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper M. Asymmetric dimethylarginine in ideopathic pulmonary hypertension. Atheroscler Thromb Vasc Biol. 2005;25:1-5 PDF
• Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel S, Bode-Böger SM. Erythropoietin increases asymmetric dimethylarginine (ADMA) in endothelial cells ? role of Dimethylarginine Dimethylaminohydrolase (DDAH). J American Soc of Nephrol. 2005, 16(4):1091-8. PDF
• Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC, Haller H, Fliser D. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.Clin Nephrol. 2004;62(4):295-300. PDF
• Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D. Subpressor dose Asymmetric dimethylarginine modulates renal blood flow through nitric oxide synthase inhibition. Kidney Blood Press Res 2004; 27 (3):143-7 PDF
• Tsikas D, Frolich JC, Kielstein JT. Nitric oxide synthesis in chronic renal failure. Are plasma S-nitrosothiol levels elevated? Clin Chim Acta 2004;339(1-2):195-7. PDF
• Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004 20;109(2):172-7. Epub 2003 Dec 08. PDF
• Kielstein JT, Bode-Boger SM, Haller H, Fliser D. Functional changes in the ageing kidney: is there a role for asymmetric dimethylarginine? Nephrol Dial Transplant 2003;18(7):1245-8. PDF
• Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 2003; 33(5):370-375. PDF
• Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int Suppl 2003;(84):37-40. PDF
• Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine (ADMA), blood pressure and renal perfusion in elderly subjets. Circulation 2003; 107(14):1891-1895. PDF
• Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13(1):170-176. PDF
• Kielstein JT, Frolich JC, Haller H, Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant 2001; 16(9):1742-1745. PDF
• Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 2001; 78:S9-13.
• Bode-Boger SM, Boger RH, Kielstein JT, Loffler M, Schaffer J, Frolich JC. Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis. J Investig Med 2000; 48(2):125-132.
• Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10(3):594-600. PDF